Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.

Five or six years ago, I attended a lecture on the science of attention. A professor who conducts research over in the medical school was talking about attention blindness, the basic feature of the human brain that, when we concentrate on one task, causes us to miss just about everything else. Because we can't see what we can't see, our lecturer was determined to catch us in the act. He had us watch a video of six people tossing basketballs back and forth, three in white shirts and three in black, and our task was to keep track only of the tosses among the people in white. The tape rolled, and everyone began counting. Everyone except me. I'm dyslexic , and the moment I saw that tape with the confusing basketball tossers, I knew I wouldn't be able to keep track of their movements, so I let my mind wander. I became curious, though, when about 30 seconds into the tape, a gorilla walked in among the players. She (we later learned a female student was in the gorilla suit) stared at the camera, beat her chest with her fist, and then went away while they continued passing the balls. When the tape stopped, the professor asked how many people had counted at least a dozen basketball tosses. Hands went up all over. He then asked who had counted 13, 14, and congratulated those who'd scored the perfect 15. Then he asked, "And who saw the gorilla?" I raised my hand and was surprised to discover I was the only person at my table and one of only three or four in the large room to do so. He'd set us up, trapping us in our own attention blindness. Yes, there had been a trick, but he wasn't the one who had played it on us. By concentrating so hard on counting, we had managed to miss the gorilla in the midst. Attention blindness is the fundamental organizing principle of the brain, and I believe that it presents us with a great opportunity. My take is different from that of many neuroscientists: Where they see the shortcomings of the individual, I sense an opportunity for cooperation. Fortunately, given the interactive nature of most of our lives in the digital age, we have the tools to control our different forms of attention and take advantage of them. It's not easy to admit that everything we've learned about how to pay attention means that we've been missing everything else. It's not easy for us logical, intelligent, confident types to admit that the very key to our success -- our ability to discover a problem and solve it, an achievement obtained in all those years in school and beyond -- may be exactly what limits us. No one ever told us that our way of seeing left out everything else.
What's the total number of basketball tosses by the players in white shirts in the video?

The homeground of FC Kuusysi is Lahden kisapuisto.
What is the home arena of FC Kuusysi?

To evaluate the effects of the sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin added to metformin for 12weeks in patients with type 2 diabetes. This dose-ranging, double-blind, placebo-controlled trial randomized 495 participants with type 2 diabetes inadequately controlled on metformin [haemoglobin A1c (HbA1c) >7 to 10%] to receive 1, 5, 10, 25, or 50mg empagliflozin once daily (QD), or placebo, or open-label sitagliptin (100mg QD), added to metformin for 12weeks. The primary endpoint was change in HbA1c from baseline to week 12 (empagliflozin groups versus placebo). Reductions in HbA1c of -0.09 to -0.56% were observed with empagliflozin after 12weeks, versus an increase of 0.15% with placebo (baseline: 7.8-8.1%). Compared with placebo, empagliflozin doses from 5 to 50mg resulted in reductions in fasting plasma glucose (-2 to -28mg/dl vs. 5mg/dl with placebo; p<0.0001) and body weight (-2.3 to -2.9kg vs. -1.2kg; p<0.01). Frequency of adverse events was generally similar with empagliflozin (29.6-48.6%), placebo (36.6%) and sitagliptin (35.2%). Hypoglycaemia rates were very low and balanced among groups. Most frequent adverse events with empagliflozin were urinary tract infections (4.0% vs. 2.8% with placebo) and pollakiuria (2.5% vs. 1.4% with placebo). Genital infections were reported only with empagliflozin (4.0%). Once daily empagliflozin as add-on therapy to metformin was well tolerated except for increased genital infections and resulted in reductions in HbA1c, fasting plasma glucose and body weight in patients with type 2 diabetes inadequately controlled on metformin monotherapy.

Which protein does empagliflozin inhibit?